Product-labeled medical uses require clinical monitoring.
Hormonal
Oxytocin
Peptide hormone with obstetric uses
Studied forChildbirth care1
FDA-approved injection for specified obstetric indications; not approved for social or cognitive enhancement.
What does it do?
A hormone used in obstetric care; nasal and oral social or sexual applications remain investigational.
Approved & studied uses
Community uses Reported, unvalidated
Obstetrics
11Labor, postpartum bleeding and incomplete-abortion management.
Social / mental
11Autism, social anxiety, trust, PTSD, depression and schizophrenia: mixed findings.
Other research
11Lactation, sexual function, pain and appetite; troches have limited evidence.
Reasons people report using it; these do not establish benefit.11
Evidence limits
View research →Obstetric labeling does not establish benefit or safe exposure for intranasal social-enhancement use.1
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Uterine hyperstimulation
Excessive contractions can harm mother and fetus.1
FDA-approved injection for specified obstetric indications; not approved for social or cognitive enhancement.
Molecular information
Amino-acid sequence
- Cys
- Tyr
- Ile
- Gln
- Asn
- Cys
- Pro
- Leu
- Gly
9 residues · N → C3
Length9 amino acids
Molecular weight · Da1007.2 Da
Formula, sequence notation & identity
Molecular formulaC43H66N12O12S23
C–Y–I–Q–N–C–P–L–GC-terminal amide and Cys1–Cys6 disulfide bridge.
CYIQNCPLG, amidated with a disulfide bridge
Chemical identity does not establish an IU-to-mg product conversion.
Pep-Pedia identity details
9 amino acids · 1,007.19 Da
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2Reference description; checked chemical identity above takes precedence when available.11
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-lifeAbout 1–6 minutes in plasma1
Route / formulationSystemic injection; label pharmacology
50%–89.1%of reference level
Illustrative model using reported human data. Shading shows the reported half-life range. No midpoint is assumed.
About 3% remaining after 5 min–30 min
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
The label gives a range without a representative mean. No single modeled half-life is selected; uterine-effect duration is a different measure.
Population: Human label data; shorter in late pregnancy/lactation
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life20 min10
Route / formulationSource page: Injectable. Exact PK route not verified.
This 20-minute reference claim differs from the 1–6-minute plasma range in the checked Pitocin label. Formulation and route matter.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 1.67 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: FDA Pitocin Label
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Mixed social-cognition outcomes
Changes varied by task and did not demonstrate broad cognitive improvement.2
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “262 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVIntravenous infusion pump | Initial 0.5–1 milliunit/minute | Continuous infusion; individualized titration | Medically indicated induction or stimulation of laborProduct label | Clinician determined | 1 |
Population Selected obstetric patients under hospital monitoring Context Label regimen for monitored hospital care. | |||||
| IVIV (diluted) | 0.5-2 mU/min initial, titrate to 1-2 mU/min every 30-60 min | Continuous IV infusion | Labor InductionReference report | Single clinical use | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Injectable | |||||
| IVIV (diluted) | 0.5-1 mU/min initial, increase gradually | Continuous IV infusion | Labor AugmentationReference report | Single clinical use | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Injectable | |||||
| IMIntramuscular | 10 units IM or 10-40 units in IV solution | Single dose after placental delivery | Postpartum Hemorrhage PreventionReference report | Single clinical use | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source route wording IM or IV infusion Source tabs Injectable | |||||
| IVIntravenous | 10 units IM or 10-40 units in IV solution | Single dose after placental delivery | Postpartum Hemorrhage PreventionReference report | Single clinical use | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source route wording IM or IV infusion Source tabs Injectable | |||||
| IVIV infusion | 10-40 units in 1L IV fluid | Rate adjusted to control bleeding | Postpartum Hemorrhage TreatmentReference report | Single clinical use | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Injectable | |||||
| IntranasalNasal spray (3-4 sprays per nostril) | 20-24 IU | Once daily or before social situations | Social anxiety/bonding enhancementReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| IntranasalNasal spray | 24-48 IU daily | Twice daily (12-24 IU AM and PM) | Autism research protocolsReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| IntranasalNasal spray | 40 IU | Before therapy sessions | PTSD therapy augmentationReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| IntranasalNasal spray | 24-40 IU | 30-45 minutes before activity | Sexual function enhancementReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| IntranasalNasal spray | 10-20 IU | Once daily | General wellness/mood supportReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| IntranasalNasal spray (1 spray per nostril) | 10 IUStarting dose | Once daily to assess tolerance | Conservative starting doseReference report | 4-12 weeks typical in research studies | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Intranasal | |||||
| OtherSublingual troche | 50-100 IU | Once daily | General wellness/bonding supportReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Oral | |||||
| OtherSublingual troche | 100 IU | 30-45 minutes before activity | Sexual function supportReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Oral | |||||
| OtherSublingual troche | 50 IUStarting dose | Once daily to assess response | Starting doseReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Single clinical use
- Break
- As medically indicated
Reported timing
Hospital/clinical setting only
Intranasal
- Use period
- 4-12 weeks typical in research studies
- Break
- 2-4 weeks between cycles (optional)
Reported timing
Morning for general use; 30-45 minutes before social/sexual activity for acute effects
Oral
- Use period
- 4-8 weeks
- Break
- 2-4 weeks between cycles (optional)
Reported timing
Allow 15-30 minutes for full dissolution and absorption
Side effects & safety
Uterine hyperstimulation
Excessive contractions can harm mother and fetus.
1Water intoxication
Prolonged infusion can cause water intoxication, including convulsions.
1Cardiovascular effects
Hypertension, hypotension and arrhythmias are described in specified settings.
1Common / route
Nausea, headache, BP changes; nasal or oral irritation.
Urgent
Excessive contractions, fetal distress, rupture signs, hypertension, confusion/seizures, allergy or severe mood changes require assessment.
Context
Pregnancy, lactation and electrolyte risks require clinician oversight.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
12 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Vasopressin
Caution reportedReceptor overlap.11
Reference report · Pep-Pedia label: Monitor CombinationSSRIs
Caution reportedMood effects uncertain.11
Reference report · Evidence context: Monitor combinationBenzodiazepines
Caution reportedSedation/BP concerns.11
Reference report · Pep-Pedia label: Use CautionAlcohol
Avoidance reportedImpairment/BP concerns.11
Reference report · Pep-Pedia label: Avoid CombinationVasoconstrictors with caudal anesthesia
Label warningSevere hypertension has been reported in this setting.1
Research contextCyclopropane anesthesia
Label warningAltered cardiovascular effects and abnormal rhythms have been reported.1
Research contextSelank
Unverified pairingUnproven anxiety pairing.11
Reference report · Pep-Pedia label: SynergisticSemax
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatiblePT-141
Unverified pairingUnproven sexual pairing.11
Reference report · Pep-Pedia label: SynergisticKisspeptin
Unverified pairingUnproven reproductive pairing.11
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingUnstudied pairing.11
Reference report · Pep-Pedia label: CompatibleProstaglandins
Unverified pairingClinical uterine potentiation.11
Reference report · Pep-Pedia label: SynergisticNo matching interactions. Try another name or filter.
Reconstitution
Pitocin is supplied as 10 units/mL; hospital infusion preparation is product specific.1
Labeled infusion preparation
The label describes adding one 10-unit/1-mL vial to 1,000 mL saline or Ringer’s lactate. This does not validate research powder or bacteriostatic water.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source describes hospital infusion preparation and continuous clinical monitoring.
- Solvents mentioned
- Compatible clinical IV solution
- Reported parameters
- Its example uses 10 biological units in 1,000 mL (10 milliunits/mL).
The page-wide BAC-water degradation and 48–72-hour claims are not specifications for all marketed oxytocin products.
Intranasal
The nasal section describes a compounded metered spray or saline-based preparation.
- Form
- Source describes a prepared product
- Reported parameters
- Reported pump example: 4–6 biological IU per 0.1 mL. · Reported preservative-free storage: 2–8°C for 48–72 hours; it also suggests frozen aliquots. · The source cautions against BAC water because of its benzyl-alcohol stability claim.
The source describes gentle mixing and avoiding vigorous shaking.
These formulation and stability claims have not been independently validated for a specific spray. Biological IU are not syringe volume units.
Oral
The oral section describes pharmacy-compounded troches, not a liquid vial.
- Form
- Source describes a prepared product
- Reported parameters
- Reported dissolution: 15–30 minutes; no chewing or swallowing intact. · Storage follows the dispensing pharmacy instructions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceFDA-approved pharmaceutical productReported appearanceClear, colorless solutionReported appearanceProper packaging and labelingReported concernCloudy or discolored solutionReported variationRequires clinical setting
11Available forms
10 units/mL prepared injection
Labeled 1-mL single-dose or 10-mL multidose presentations; no mg conversion is inferred.1
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.11
Full storage notes from Pep-Pedia
11Refrigerate 2-8°C, protect from light
Refrigerate at 2-8°C, protect from light
Room temperature or refrigerated per pharmacy instructions
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
Human trialsSource context
Social effects vary; nasal findings cannot establish troche effectiveness. Reference interaction labels are not safety clearance.
Compound identity & other names
Oxytocin is a peptide hormone used in supervised obstetric care. Experimental social-cognition findings involve different formulations and outcomes from its approved obstetric use.
FDA-approved injection for specified obstetric indications; not approved for social or cognitive enhancement.
How it may work
Oxytocin receptors regulate uterine contraction; central effects depend on route and context.11
Established obstetric role
Pitocin is labeled for medically indicated induction or augmentation of labor and control of postpartum uterine bleeding.
1Recent cognition findings are mixed
The 2026 crossover study found exploratory social-engagement changes but no improved emotion recognition, and harmful-intention recognition became less accurate.
2Research areas and evidence gaps
Obstetric care. Product-labeled medical uses require clinical monitoring.1
- Obstetric labeling does not establish benefit or safe exposure for intranasal social-enhancement use.
Community reports Unvalidated
Pep-Pedia discusses obstetric care and social-cognition research.4
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Added a 2026 frontotemporal-dementia crossover study and current Pitocin labeling, with distinct routes and indications.
- Checked
- 2026-10-12
- Search
- "oxytocin" 2025 2026 randomized trial
- Catalog
- Pep-Pedia ↗ · 5 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Pitocin (oxytocin injection) prescribing informationPrimary source checked
AI-PREPARED SUMMARY
Approved obstetric solution with supervised infusion instructions. The label describes uterine hyperstimulation, water intoxication and cardiovascular interactions. It does not approve social or cognitive enhancement.
Established obstetric role
Pitocin is labeled for medically indicated induction or augmentation of labor and control of postpartum uterine bleeding.
Additional research · Checked 2026-10-12
2Oxytocin reduces anger bias, harm-intention recognition, and self-focus in behavioral variant frontotemporal dementia: a randomized double-blind placebo-controlled crossover trialAbstract checked
AI-PREPARED SUMMARY
The trial found exploratory social-engagement changes, no improvement in emotion recognition and reduced accuracy for harmful intentions. These mixed results do not establish general social enhancement.
Recent cognition findings are mixed
The 2026 crossover study found exploratory social-engagement changes but no improved emotion recognition, and harmful-intention recognition became less accurate.
Additional research · Checked 2026-10-12
3PubChem: OxytocinPrimary source checked
AI-PREPARED SUMMARY
Chemical registry for cyclic nonapeptide oxytocin.
Additional research · Checked 2026-10-12
4Pep-Pedia: OxytocinCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
5Intranasal Oxytocin for Obesity (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The 61-person trial did not produce weight loss, despite lower intake at test meals and changes in mental-health quality of life.
Reported population / model
Human RCT
Reported study details
N=61 adults with obesity · 24 IU four times daily · 8 weeks · NEJM Evidence
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Oxytocin Effects on Social Cognition in Schizophrenia (2023)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The primary social-cognition comparison did not favor oxytocin; some secondary or within-group measures improved.
Reported population / model
Human RCT
Reported study details
N=68 · 24 IU twice daily · 12 weeks · Schizophrenia Research
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Intranasal Oxytocin in Autism Spectrum Disorder (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The 290-participant autism trial found no significant improvement in social functioning versus placebo after 24 weeks.
Reported population / model
Human Phase 2 RCT
Reported study details
N=290 children/adolescents · 48 IU daily · 24 weeks · NEJM
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Oxytocin Augmented Prolonged Exposure Therapy for PTSD (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports lower PTSD/depression symptoms during exposure therapy; the combined intervention makes treatment context essential.
Reported population / model
Human RCT
Reported study details
Veterans with PTSD · 40 IU intranasal · Combined with PE therapy
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Chronic Intranasal Oxytocin Effects on Male Sexual Function (2012)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A single case described improvements in several sexual-function domains; one uncontrolled observation cannot establish efficacy.
Reported population / model
Human case study
Reported study details
40 IU intranasal · Multi-week chronic use
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Pep-Pedia: Oxytocin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 20 min and a peak time of 30 min. Stated attribution: FDA Pitocin Label. This 20-minute reference claim differs from the 1–6-minute plasma range in the checked Pitocin label. Formulation and route matter. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
11Pep-Pedia: Oxytocin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12